Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
EMBER500RNA Prestain Loading Dye allows single-step denaturing, loading, and bright RNA staining on regular agarose gels
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Celltrion plans to provide dual treatment options for COVID-19; Regkirona for hospitalised patients and a nebulised cocktail therapy (CT-P63 in combination with Regkirona) for at- home settings
Aim of the virtual conference is to facilitate Indian Pharma Industry adopt Green & Sustainable Chemistry as a tool to enhance Economic & Environmental Competitiveness
The newly launched centre in Mumbai is part of the company’s ambition to be present in 100 cities across the country within two years.”
The Home Healthcare market is expected to be US $ 14.2 by 2025
Subscribe To Our Newsletter & Stay Updated
